{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:51:15Z","timestamp":1783986675288,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004944","name":"Naresuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006440","name":"Naresuan University Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.06.017","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T03:38:19Z","timestamp":1685936299000},"page":"4335-4340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-5863","authenticated-orcid":false,"given":"Supawadee","family":"Makanut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-5436","authenticated-orcid":false,"given":"Apirath","family":"Wangteeraprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wittawat","family":"Jitpewngam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatuporn","family":"Ngoenkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutatip","family":"Pongcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.017_b0005","unstructured":"World Health Organization. Coronavirus disease (COVID-19) dashboard. https:\/\/covid19.who.int. accessed on June 30th, 2022."},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.017_b0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2023.06.017_b0015","doi-asserted-by":"crossref","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey [published correction appears in Lancet. 2022 Jan 29;399(10323):436]. Lancet. 2021;398(10296):213\u201322. http:\/\/doi.org\/10.1016\/S0140-6736(21)01429-X","DOI":"10.1016\/S0140-6736(21)01429-X"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.017_b0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.06.017_b0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.017_b0030","unstructured":"World Health Organization. Coronavirus disease (COVID-19) dashboard. https:\/\/covid19.who.int\/region\/searo\/country\/th. Accessed on October 26th, 2022."},{"key":"10.1016\/j.vaccine.2023.06.017_b0035","doi-asserted-by":"crossref","unstructured":"Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(31):1059-1062. Published 2021 Aug 6. http:\/\/doi.org\/10.15585\/mmwr.mm7031e2.","DOI":"10.15585\/mmwr.mm7031e2"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.017_b0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1056\/NEJMoa2116063","article-title":"Covid-19 Vaccine Effectiveness in New York State","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2023.06.017_b0045","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.017_b0050","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"6561","key":"10.1016\/j.vaccine.2023.06.017_b0055","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.vaccine.2023.06.017_b0060","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning Immunity after the BNT162b2 Vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2023.06.017_b0065","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMc2203165","article-title":"Effectiveness of homologous and heterologous covid-19 boosters against omicron","volume":"386","author":"Accorsi","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2023.06.017_b0070","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.017_b0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2023.06.017_b0080","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1016\/j.vaccine.2021.10.007","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon","volume":"39","author":"Moghnieh","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.017_b0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.017_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jmv.27350","article-title":"SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen","volume":"94","author":"Keskin","year":"2022","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.017_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"10324","key":"10.1016\/j.vaccine.2023.06.017_b0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.017_b0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vaccines10040556","article-title":"Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody","volume":"10","author":"Lai","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.017_b0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jalm\/jfab173","article-title":"Long-term comparison of 7 SARS-CoV-2 antibody assays in the North Zealand covid-19 cohort","volume":"7","author":"Wiwe","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.017_b0115","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/microorganisms9081786","article-title":"Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: A report for up to 10 months after infection. Microorganisms 2021, 9, 556","volume":"9","author":"Schulte-Pelkum","year":"2021","journal-title":"Microorganisms."},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.017_b0120","doi-asserted-by":"crossref","first-page":"e0113121","DOI":"10.1128\/Spectrum.01131-21","article-title":"A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies","volume":"9","author":"Solastie","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.017_b0125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jmii.2021.02.003","article-title":"Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan","volume":"54","author":"Lin","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"issue":"18","key":"10.1016\/j.vaccine.2023.06.017_b0130","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against Omicron in Israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2023.06.017_b0135","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth dose of BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"386","author":"Magen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.017_b0140","article-title":"Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study","volume":"377","author":"Gazit","year":"2022","journal-title":"BMJ."},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.017_b0145","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41591-022-01832-0","article-title":"Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years","volume":"28","author":"Arbel","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.vaccine.2023.06.017_b0150","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.017_b0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamainternmed.2022.2658","article-title":"Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities","volume":"182","author":"Muhsen","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.017_b0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24657","article-title":"Israeli-Hospitals 4th Vaccine Working Group. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel","volume":"5","author":"Cohen","year":"2022","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.vaccine.2023.06.017_b0165","article-title":"Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study","volume":"378","author":"Grewal","year":"2022","journal-title":"BMJ."},{"issue":"29","key":"10.1016\/j.vaccine.2023.06.017_h9035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.15585\/mmwr.mm7129e1","article-title":"Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2\/BA.2.12.1 sublineages predominated - VISION network, 10 States, December 2021-June 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2023.06.017_h0170","unstructured":". . http:\/\/doi.org\/."},{"key":"10.1016\/j.vaccine.2023.06.017_b0175","unstructured":"Interim recommendations for heterologous COVID-19 vaccination schedules. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules, accessed 6 August 2022."},{"key":"10.1016\/j.vaccine.2023.06.017_b0180","unstructured":"Good practice statement on the use of second booster doses for COVID-19 vaccines. World Health Organization; 2022. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-good-practice-statement-second-booster, accessed on 18 August 2022."},{"key":"10.1016\/j.vaccine.2023.06.017_b0185","article-title":"Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand: a test-negative, case-control study","volume":"10","author":"Intawong","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.017_b0190","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:28:26Z","timestamp":1759404506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23006667"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}